About 4th Annual Pharma Market Access and Pricing Asia

New drug launch and speed to the market were disrupted by COVID-19. What are the eventual impacts on the launch timelines of new products? And what are the risks and implications of commercialisation? How will manufacturers’ priority to develop COVID-19 diagnostics and treatments affect appraisal and price negotiations for non-COVID-19 therapeutics?

Delivered digitally, the 4th Annual Market Access and Pricing Asia envisions the outlook for global and APAC markets.  Leading manufacturers will outline speed-to-market strategies, and approaches to pricing and market access negotiations.

2020 Highlights:

  • Agile market access strategies for Non-COVID-19 drugs
  • Reimbursement – challenges, models and strategies
  • Meeting regional Healthcare policies, achieving fair pricing and drug affordability
  • Maximising RWE applications and drawing value in the Asian context
  • Introducing HTA for growing economies
  • Regulatory, procurement, and strategic pricing roadmap
  • Adapting commercialisation strategies in light of COVID-19
  • Contracting and payment models
  • Regional case studies on access and affordability

Very informative and interactive, the content of the presentation is able to promote thinking + relearning of current strategy, happy to get to know a few friends.

– Executive Director, Xepa-Soul Pattinson (Malaysia) Sdn Bhd

Beyond expectation, knowledgeable & insightful speaker.

– Dioko, MAPA, Novo Nordisk